Growth hormone axis · ghrelin receptor agonists
Arkham Labs editorial/Published 8 September 2026/Revised 12 September 2026/Corrections policy
Secretagogues acting at the growth hormone secretagogue receptor. Human endocrine pharmacology is established across most of the family — these compounds demonstrably raise growth hormone in people. What is missing is any trial showing that doing so produces a clinical benefit.
Five of these six guides carry Early Clinical, which makes this the most trial-bearing family in the library. It is also the clearest demonstration of what that grade does and does not mean.
Early Clinical records that at least one human trial has been published. It does not record that the trial succeeded. Ipamorelin‘s single randomised controlled trial, in postoperative ileus, was null on its endpoints. Ibutamoren has two randomised trials in a clinical indication, both in hip fracture recovery, and neither found significant improvement in functional performance. The compounds in this family have well-characterised endocrine pharmacology in humans; what they do not have is a trial that met its endpoint.
- Guides in this family
- 6
- Peer-reviewed sources
- 112
- Grades represented
- Preclinical 1 · Early 5
- GHRP-2+Early Clinical
- GHRP-6+Early Clinical
- Hexarelin+Early Clinical
- Ibutamoren (MK-677)+Early Clinical
- Ipamorelin+Early Clinical
- Ipamorelin and CJC-1295◦Preclinical
The clearest demonstration in the library that Early Clinical records a trial having been run, not a trial having succeeded — Ipamorelin’s was null on its endpoints.
For laboratory research use only. Not for human consumption. Nothing here is medical advice.